GW320659 for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children
- Joseph Deveaugh-Geiss,
- C. Keith Conners,
- Elias H. Sarkis,
- Paul K. Winner,
- Lawrence D. Ginsberg,
- J. Michael Hemphill
- Duke University,
- GlaxoSmithKline,
- Alachua Family Psychiatry,
- Premiere Res. Inst. P. Beach Neurol.,
- Red Oak Psychiatric Associates,
- Georgia Neurological Institute
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Objective: To assess the safety, tolerability, and efficacy of GW320659, a chemically novel inhibitor of norepinephrine and dopamine reuptake, in pediatric attention-deficit/hyperactivity disorder (ADHD). Method: This was a multicenter, open-label, dose-titration study of seven daily dose levels of GW320659: 1.25, 2.5, 5, 7.5, 10, 12.5, and 15 mg. Treatment began with the lowest dose of GW320659 and increased weekly until subjects (mean age 9.1 years) achieved a maximum acceptable dose. Subjects remained at their maximum acceptable dose for a 4-week treatment period. The key efficacy end-point was clinical response (Clinical Global Impressions of Improvement score of 1 or 2 and an improvement of 5 or more points on at least one of the Conners Parent or Teacher Rating Scales T score). Other end-points included assessments of safety and of quality of life using the Child Health Questionnaire Parent Form 28 (CHQ-PF28). Results: Fifty-one subjects entered the titration phase and 46 subjects completed the study. During the treatment phase, these 46 subjects received a mean dose of 14.2 mg/day and the maximum exposure to GW320659 was 11 weeks. At the end of the treatment period, 76% of subjects showed improvement with GW320659 and there were significant improvements in 7 of the 12 subscales of the CHQ-PF28 compared with baseline (p < .05). Adverse events were generally mild; only five subjects required downward titration because of adverse events (three psychiatric, one neurological and urological, one cardiovascular), and no subject withdrew because of adverse events. Conclusions: GW320659 may have clinically relevant efficacy in pediatric ADHD and was well tolerated in this short-term initial study in children.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 914-920 (7 pages)Journal (Volume, Issue Number)
Journal of the American Academy of Child and Adolescent Psychiatry (Volume 41, Issue 8)Publication milestones
- Published - 08/2002
Publication status
Published - 08/2002
ISSN
0890-8567Publication IDs
- Scopus: 0036675147
- PubMed: 12162627
Publication metrics
Metrics
SciVal
FWCI
2.76
SciVal
Author count
11
SciVal
citations
30
SciVal
Paper percentile
77
Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Mentions
3
Captures
32
Citation count
32
Funding Details
This study (protocol ADDA2002) was sponsored by Glaxo Wellcome Inc. The authors thank Ruby Terracciano for writing and editing assistance.
FunderFunding numbers
Glaxo Wellcome Inc
-